Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Cancer Prevention Month: Get ACRO Health Gift Cards! Cancer Prevention Month: Get ACRO Health Gift Cards!
Fill out organ-on-a-chip questionnaire to win a FREE gift! Fill out organ-on-a-chip questionnaire to win a FREE gift!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Kat. Nr. | Arten | Produktbeschreibung | Struktur | Reinheit | Merkmal |
---|---|---|---|---|---|
TNB-H5220 | Human | Human Osteoprotegerin / TNFRSF11B Protein, His Tag |
|
||
TNB-H5259 | Human | Human Osteoprotegerin / TNFRSF11B Protein, Fc Tag |
|
Loaded Human Osteoprotegerin, His Tag (Cat. No. TNB-H5220) on HIS1K Biosensor, can bind Human TRAIL with an affinity constant of 0.831 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Denosumab biosimilar (Qilu Pharma) | QL-1206 | Approved | Qilu Pharmaceutical Co Ltd | 鲁可欣 | Mainland China | Osteoporosis, Postmenopausal | Qilu Pharmaceutical Co Ltd | 2023-09-28 | Solid tumours; Bone metastases; Osteoporosis, Postmenopausal | Details |
Narlumosbart | JMT-103 | Approved | Shanghai Jmt-Bio Inc | 津立生 | Mainland China | Giant Cell Tumor of Bone | Shanghai Jmt-Bio Inc | 2023-09-05 | Solid tumours; Bone metastases; Osteoporosis; Osteoporosis, Postmenopausal; Hypercalcemia; Neoplasms; Giant Cell Tumor of Bone; Glucocorticoid-induced osteoporosis | Details |
Denosumab biosimilar(Reliance Life Sciences) | R-TPR-045 | Approved | Reliance Life Sciences | DenosuRel | India | Osteoporosis, Postmenopausal; Bone metastases | Reliance Life Sciences | 2022-02-01 | Bone metastases; Osteoporosis, Postmenopausal | Details |
Denosumab biosimilar (Mabwell) | 9-MW-0311; 9MW0321; 9-MW0321; 9MW-0321; 9-MW-0321; TK-006; MW-032; MW-031; 9MW0311; 9-MW0311; 9MW-0311 | Approved | Jiangsu T-Mab Bio-Pharmaceuticals Co Ltd | 迈利舒 | Mainland China | Osteoporosis, Postmenopausal | Jiangsu T-Mab Bio-Pharmaceuticals Co Ltd | 2023-03-28 | Bone metastases; Solid tumours; Osteoporosis; Osteoporosis, Postmenopausal; Breast Neoplasms; Bone Neoplasms | Details |
Denosumab | NSC-744010; AMG-162 | Approved | Amgen Inc | Prolia, Xgeva, Pralia, Ranmark, 普罗力 | EU | Osteoporosis, Postmenopausal | Amgen Europe Bv | 2010-05-26 | Lymphoma; Prostatic Neoplasms, Castration-Resistant; Feeding and Eating Disorders; Breast Neoplasms; Prostatic Neoplasms; Giant Cell Tumors; Osteosarcoma; Arthropathy, Neurogenic; Osteogenesis Imperfecta; Giant Cell Tumor of Bone; Bone Neoplasms; Breast Diseases; Fractures, Bone; Multiple Myeloma; Lung Neoplasms; Osteoblastoma; Granuloma, Giant Cell; Thyroid Neoplasms; Lymphoma, Non-Hodgkin; Glucocorticoid-induced osteoporosis; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Fibroma; Crohn Disease; Anorexia Nervosa; Fibrous Dysplasia of Bone; Kidney Neoplasms; Solid tumours; Cataract; Endocrine Gland Neoplasms; Head and Neck Neoplasms; Hematopoietic stem cell transplantation (HSCT); Hematologic Neoplasms; Bone Diseases, Metabolic; Osteoporosis; Carcinoma; Pain; Parathyroid Neoplasms; Bone metastases; Osteoporosis, Postmenopausal; Smoldering Multiple Myeloma; Colonic Neoplasms; Hypercalcemia; Neoplasms; Chondroblastoma; Kidney Diseases; Carcinoma, Ovarian Epithelial; Bone Disease | Details |
Denosumab biosimilar (Boan Biopharma/Luye) | LY-01011; BA-1102; BA-6101; LY-06006 | Approved | Shandong Boan Biotechnology Co Ltd, Luye Pharma Group Ltd | Mainland China | Osteoporosis, Postmenopausal | Shandong Boan Biotechnology Co Ltd | 2022-11-10 | Bone metastases; Solid tumours; Osteoporosis; Osteoporosis, Postmenopausal; Neoplasms; Multiple Myeloma; Giant Cell Tumor of Bone; Bone Neoplasms; Neoplasm Metastasis | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Recombinant human anti-RANKL momoclonal antibody (Qilu Pharmaceutical) | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Osteoporosis, Postmenopausal; Neoplasms | Details | |
Recombinant human anti-RANKL antibody (Innovent Biologics) | IBI-307 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Osteoporosis | Details |
Denosumab biosimilar(Mabxience) | Phase 3 Clinical | Mabxience Sa | Osteoporosis, Postmenopausal | Details | |
Recombinant anti-RANKL monoclonal antibody(Jiangsu Pacific-Meinuoke) | Phase 1 Clinical | Jiangsu Pacific-Meinuoke Bio-Pharmaceutical Co Ltd | Osteoporosis, Postmenopausal | Details | |
Denosumab biosimilar(Alvotech Swiss) | AVT-03 | Phase 3 Clinical | Alvotech Swiss Ag | Osteoporosis, Postmenopausal | Details |
Denosumab biosimilar (Hualan Biological Engineering) | Phase 3 Clinical | Hualan Genetic Engineering Co Ltd | Solid tumours; Bone metastases; Osteoporosis, Postmenopausal | Details | |
Denosumab biosimilar (Henlius ) | HLX-14; HLX14 | Phase 3 Clinical | Shanghai Henlius Biotech Inc | Osteoporosis, Postmenopausal | Details |
Denosumab biosimilar (Intas Biopharmaceuticals) | Phase 3 Clinical | Intas Biopharmaceuticals | Osteoporosis, Postmenopausal | Details | |
Denosumab biosimilar(Fresenius Kabi) | FKS-518 | Phase 3 Clinical | Fresenius Kabi Swissbiosim Gmbh | Osteoporosis, Postmenopausal | Details |
Denosumab biosimiliar (Celltrion) | CT-P41 | Phase 3 Clinical | Celltrion Inc | Osteoporosis, Postmenopausal | Details |
MV-088 | MV-088 | Phase 1 Clinical | Kpc Pharmaceuticals Inc | Osteoporosis, Postmenopausal | Details |
GB-223 | GB-223 | Phase 1 Clinical | Genor Biopharma Co Ltd | Solid tumours; Bone metastases; Osteoporosis, Postmenopausal; Bone Neoplasms; Giant Cell Tumor of Bone | Details |
KP-46 | KP-46; FFC-11; LX-001; AP-002 | Phase 2 Clinical | University Of Heidelberg, Meram | Solid tumours | Details |
Denosumab biosimilar (AryoGen) | Phase 3 Clinical | Aryogen Biopharma | Osteoporosis | Details | |
LZM-004 | LZM-004 | Phase 1 Clinical | Livzon(Group) Pharmaceutical Factory | Bone metastases | Details |
TVB-009 | TVB-009 | Phase 3 Clinical | Teva Pharmaceutical Industries Ltd | Osteoporosis, Postmenopausal | Details |
Denosumab biosimilar(Shanghai Hansoh) | HS-20090; HS-20090-2 | Phase 3 Clinical | Shanghai Hansoh Biomedical Co Ltd, Jiangsu Hansoh Pharmaceutical Group Co Ltd | Bone metastases; Solid tumours; Neoplasms; Osteoporosis, Postmenopausal; Bone Diseases; Hypercalcemia; Multiple Myeloma; Giant Cell Tumor of Bone; Nutritional and Metabolic Diseases | Details |
Denosumab biosimilar (Samsung Bioepis) | SB-16 | Phase 3 Clinical | Samsung Bioepis Co Ltd | Osteoporosis, Postmenopausal | Details |
Denosumab biosimilar(Enzene Biosciences) | ENZ-215 | Phase 3 Clinical | Enzene Biosciences Ltd | Osteoporosis, Postmenopausal | Details |
Recombinant human anti-RANKL antibody (Hisun Pharma) | HS629 | Phase 1 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Bone metastases; Solid tumours | Details |
RGB-14-P | RGB-14-P | Phase 3 Clinical | Gedeon Richter Plc | Osteoporosis, Postmenopausal | Details |
CMAB807 | CMAB-807; CMAB807X | Phase 3 Clinical | Shanghai Biomabs Pharmaceuticals Co Ltd, Shanghai Maitai Yabo Biotechnology Co Ltd | Osteoporosis, Postmenopausal | Details |
This web search service is supported by Google Inc.